Eugenol from Musa acuminate, a potential Antagonist against c-Met: in Non-small cell lungs cancer chemotherapy in silico study. Bioinformatics and Biology insights.

Simple item page
dc.contributor.authorGeorge, Oche A.
dc.contributor.authorSulaiman, A.Faoziyat
dc.contributor.authorOlanrewaju, John A
dc.contributor.authorNwufoh, Chika N
dc.contributor.authorNzikahyel, Simon
dc.contributor.authorAdebo, Adeola O
dc.contributor.authorToyin, Soyinka
dc.contributor.authorAlakanse, Suleiman O
dc.contributor.authorSeyi, Bankole
dc.date.accessioned2020-01-30T11:16:26Z
dc.date.available2020-01-30T11:16:26Z
dc.date.issued2018-06-22
dc.descriptionDocking studies and ADMET evaluation of eugenol with c-Met showed that this ligand is a drug-gable molecule which docks well with c-Met target. Therefore, eugenol molecule plays an important role in inhibiting c-Met and thus should be implicated as a potential agent in cancer therapy.en_US
dc.description.abstractc-Met (Mesenchymal Epithelial Transition) inhibitors are regarded as a kind of novel drugs in the treatment of non-small cell lung cancer (NSCLC).The current FDA-approved c-Met inhibitors which include crizotinib and cabozantinib have been reported to present an adverse effect when used in NSCLC therapy. This ranges from chest pain, unusual bleeding of the nose and mouth, fever and jaundice. In view of this, research is focus on identifying more potent compounds with no adverse effects that can be used in the treatment of NSCLC. The aim of this study is to out-source from plant sources (musa acuminate) for the best-in-class drug-gable compound via computational tools. For this, twenty-eight (28) chemical compounds (phytochemicals) obtained from musa acuminate and retrieved from literatures were screened for their inhibitory effects on c-Met. Eugenol was the lead compound with a binding energy of -5.7.0kcal/mol. Computational docking analysis was performed using PyRx, AutoDock Vina option based on scoring functions and the target was validated so as to ensure that the right target was used for this analysis. These results indicated that eugenol could be one of the potential ligands to treat NSCLC.en_US
dc.identifier.citation33) George Oche A., Sulaiman A. Faoziyat, Olanrewaju John A., Nwufoh Chika N., Nzikahyel Simon, Adebo Adeola O., Toyin Soyinka., Alakanse Suleiman O. and Seyi Bankole. Eugenol from Musa acuminate, a potential Antagonist against c-Met: in Non-small cell lungs cancer chemotherapy in silico study. Bioinformatics and Biology insights. Published by Villupuram International Journal of Current Advanced Research, (IJCAR) India. ISSN 2319-6505. Manuscript ID BBI-2018-0004. Accepted on the 22nd of June 2018.en_US
dc.identifier.issn2319-6505
dc.identifier.urihttp://hdl.handle.net/123456789/3612
dc.language.isoen_USen_US
dc.publisherInternational Journal of Current Advanced Research, (IJCAR) Indiaen_US
dc.subjectc-Meten_US
dc.subjectmusa acuminateen_US
dc.subjectEugenolen_US
dc.titleEugenol from Musa acuminate, a potential Antagonist against c-Met: in Non-small cell lungs cancer chemotherapy in silico study. Bioinformatics and Biology insights.en_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
2019 Eugenol in silico current.pdf
Size:
698.17 KB
Format:
Adobe Portable Document Format
Description:
Eugenol, from Musa acuminate, a Potential Antagonist against c-Met in Non- Small Cell Lung Cancer Chemotherapy: in silico study
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.69 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections